--- title: "Canopy Growth (TSE:WEED) Stock Price Down 0.6% - Time to Sell?" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/276986125.md" description: "Canopy Growth (TSE:WEED) shares fell 0.6% to C$1.60, with trading volume down 43% from average levels. Analysts have set new price targets, with Sanford C. Bernstein lowering theirs from C$5.30 to C$2.50, while ATB Cormark reduced it from C$1.60 to C$1.40. The stock has a consensus rating of \"Reduce\" and a price target of C$1.95. Canopy Growth reported a negative EPS of C($0.18) for the last quarter and is expected to post -0.69 EPS for the current fiscal year. The company specializes in medical cannabis products in Canada." datetime: "2026-02-26T05:21:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276986125.md) - [en](https://longbridge.com/en/news/276986125.md) - [zh-HK](https://longbridge.com/zh-HK/news/276986125.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/276986125.md) | [English](https://longbridge.com/en/news/276986125.md) # Canopy Growth (TSE:WEED) Stock Price Down 0.6% - Time to Sell? Canopy Growth Corp (TSE:WEED - Get Free Report)'s stock price was down 0.6% during trading on Wednesday . The stock traded as low as C$1.59 and last traded at C$1.60. Approximately 1,323,345 shares traded hands during trading, a decline of 43% from the average daily volume of 2,306,358 shares. The stock had previously closed at C$1.61. Get **Canopy Growth** alerts: ## Analysts Set New Price Targets Several research firms have recently weighed in on WEED. Sanford C. Bernstein reduced their price objective on Canopy Growth from C$5.30 to C$2.50 in a research note on Wednesday, January 14th. Benchmark raised shares of Canopy Growth from a "sell" rating to a "hold" rating in a research report on Monday, November 10th. Finally, ATB Cormark Capital Markets reduced their price target on shares of Canopy Growth from C$1.60 to C$1.40 and set an "underperform" rating on the stock in a research report on Thursday, December 11th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Reduce" and a consensus price target of C$1.95. **View Our Latest Analysis on WEED** ## Canopy Growth Trading Down 0.6% The firm has a market cap of C$604.58 million, a price-to-earnings ratio of -0.86, a price-to-earnings-growth ratio of -0.01 and a beta of 1.76. The company has a quick ratio of 2.32, a current ratio of 1.39 and a debt-to-equity ratio of 120.38. The business has a 50 day moving average price of C$1.64 and a 200-day moving average price of C$1.79. Canopy Growth (TSE:WEED - Get Free Report) last released its quarterly earnings results on Friday, February 6th. The company reported C($0.18) EPS for the quarter. Canopy Growth had a negative return on equity of 108.18% and a negative net margin of 201.27%.The company had revenue of C$74.54 million for the quarter. As a group, research analysts expect that Canopy Growth Corp will post -0.69 EPS for the current fiscal year. ## Canopy Growth Company Profile (Get Free Report) Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. ## Featured Stories - Five stocks we like better than Canopy Growth - The gold chart Wall Street is terrified of… - America’s 1776 happening again - This makes me furious - Buy this Gold Stock Before May 2026 - What a Former CIA Agent Knows About the Coming Collapse _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Canopy Growth Right Now? Before you consider Canopy Growth, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Canopy Growth wasn't on the list. While Canopy Growth currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### 相關股票 - [Canopy Growth (CGC.US)](https://longbridge.com/zh-HK/quote/CGC.US.md) ## 相關資訊與研究 - [Canopy Growth Targets Value Segment With High-THC Deelish Brand Launch](https://longbridge.com/zh-HK/news/281224476.md) - [Thinking About Buying Canopy Growth Stock? You May Want to Wait for This to Happen First](https://longbridge.com/zh-HK/news/281078456.md) - [Boardwalktech Raises C$384,800 in First Tranche of Private Placement](https://longbridge.com/zh-HK/news/281385232.md) - [Canopy Growth’s Apollo Clinics Named Top Medical Cannabis Provider by Toronto Star Readers](https://longbridge.com/zh-HK/news/281022430.md) - [VSBLTY to Raise Up to C$7 Million in Private Placement, Grants New RSUs](https://longbridge.com/zh-HK/news/281104034.md)